Program overview
Connecticut, like other states, has a prescription drug cost transparency program. Prescription transparency requires drug manufacturers, pharmacy benefit managers, health plans, and others to report information that explains high price increases and high-priced new drugs.
The laws focus on a list of 10 outpatient prescription drugs determined by the Office of Health Strategy (OHS) as:
The laws focus on a list of 10 outpatient prescription drugs determined by the Office of Health Strategy (OHS) as:
- A substantial cost to the state or
- Critical to public health
Program highlights
Prescription drug costs transparency filings manual and guide
See which information should be reported, review technical terms and definitions, and learn how to register for and use the prescription drug reporting system required under Connecticut General Statutes § 19a-754b.
Prescription drug reporting (PDRS)
Prescription drug sponsors and manufacturers use the PDRS to report notices, information, and data as required under Connecticut General Statutes (C.G.S.) §19a-754b.
Legislation for Prescription Drug Reporting
Sponsors and manufacturers of certain prescription drugs are required to adhere to the prescription drug reporting process. Connecticut General Statute § 19a-754b(b) describes requirements for notices from sponsors of new pipeline and biosimilar drugs; 19a-754b(d) covers filings from manufacturers of pipeline drugs; and 19a-754b(c)(2) is about filings from manufacturers of high-cost drugs.